TGF- 1 induces proteinase-activated receptor 2 (PAR2) expression in endometriotic stromal cells and stimulates PAR2 activation-induced secretion of IL-6
Open Access
- 5 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 26 (7) , 1892-1898
Abstract
Proteinase-activated receptor 2 (PAR2) is a G-protein-coupled receptor that is activated by several serine proteases. PAR2 activation in endometriotic stromal cells (ESCs) has been implicated in the development of endometriosis but the regulatory mechanism of PAR2 expression in ESC is unknown. Our objective was to study the mechanism by which PAR2 expression may be regulated in endometriotic lesions. Primary cultures of ESCs were treated with transforming growth factor-β (TGF-β) 1, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and the expression of PAR2 was examined by real-time quantitative PCR. ESCs pretreated with or without TGF-β1 were treated with PAR2 agonist peptide (PAR2AP) and the secretion of the pro-endometriotic cytokine, IL-6, was measured using a specific enzyme-linked immunosorbent assay. Effects of TGF-β type 1 inhibitor, SB431542, and PAR2 small interfering RNA (siRNA) on the TGF-β1 stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion were also evaluated. To study intracellular signaling, effects of inhibitors of mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K) and of Smad4 siRNA on the TGF-β1-induced PAR2 gene expression were studied. Only TGF-β1, but neither TNF-α nor IL-1β, increased gene expression of PAR2. Activation of PAR2 with PAR2AP increased the secretion of IL-6 from ESCs. As expected, TGF-β1 pretreatment dose-dependently enhanced the PAR2AP-induced increase in IL-6 secretion from ESCs. Treatment of ESCs with the TGF-β type 1 inhibitor, SB431542, inhibited both TGF-β1-stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion. Transfection of ESCs with PAR2 siRNA produced a similar inhibition of IL-6 secretion. The TGF-β1-induced increase in PAR2 gene expression was repressed by inhibition of p38 MAPK, p42/44 MAPK or PI3K, but not by knockdown of Smad4 expression. In view of significant roles of PAR2 and IL-6 in endometriosis, the TGF-β1-induced increase in PAR2 expression may be an elaborate mechanism that augments the progression of the disease.Keywords
This publication has 39 references indexed in Scilit:
- Interleukin-4 induces expression of eotaxin in endometriotic stromal cellsFertility and Sterility, 2010
- Inflammatory cytokines differentially up-regulate human endometrial haptoglobin production in women with endometriosisHuman Reproduction, 2010
- Interleukin-4 Stimulates Proliferation of Endometriotic Stromal CellsThe American Journal of Pathology, 2008
- Role of transforming growth factor-β superfamily signaling pathways in human diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2008
- Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science studyArthritis Research & Therapy, 2007
- Analysis of protease‐activated receptor‐1 and ‐2 in human scar formationThe Journal of Pathology, 2007
- FR 167653, a p38 mitogen-activated protein kinase inhibitor, suppresses the development of endometriosis in a murine modelJournal of Reproductive Immunology, 2006
- Is Endometriosis Really Associated with Pain?Gynecologic and Obstetric Investigation, 2002
- Interleukin-6 Differentially Stimulates Haptoglobin Production by Peritoneal and Endometriotic Cells in Vitro: A Model for Endometrial-Peritoneal Interaction in EndometriosisThe Journal of Clinical Endocrinology & Metabolism, 2001
- Transforming Growth Factor‐β Isoforms and Receptors in Endometriotic Cysts of the Human OvaryAmerican Journal of Reproductive Immunology, 1999